Free Delivery Over $100
|
|
|||
|
||||
OverviewThe COVID-19 pandemic has affected the entire world in an unprecedented way, and this book provides an overview of the historical facts as well as ongoing approaches to tackle the COVID-19 pandemic. Experts of the respective domains provide details on anti-SARS-CoV-2 drug strategies, including repurposing drugs used for other indications and the development of novel drugs looking at different approaches to target virus entry and replication. COVID-19 vaccine development based on inactivated and attenuated live virus, protein subunit and peptide-based vaccines and utilization of vaccine candidates based on viral vectors, DNA and RNA are presented for both preclinical studies and clinical trials. Key Features Explains the background of the COVID-19 pandemic, the current progress in the development of treatments and prevention of COVID-19 including future aspects of dealing with the pandemic Serves as a timely repository of knowledge on COVID-19 for researchers and medical professionals engaged in its management Full Product DetailsAuthor: Debmalya Barh (UFMG, Brazil.) , Kenneth Lundstrom (PanTherapeutics, Switzerland)Publisher: Taylor & Francis Ltd Imprint: CRC Press Weight: 0.440kg ISBN: 9781032040622ISBN 10: 1032040629 Pages: 222 Publication Date: 04 March 2022 Audience: Professional and scholarly , College/higher education , Professional & Vocational , Postgraduate, Research & Scholarly Format: Paperback Publisher's Status: Active Availability: In Print  This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of ContentsReviewsAuthor InformationDr. Debmalya Barh is currently a Visiting Full Professor (Titular, Grade-E) at the Department of Genetics, Ecology and Evolution, Institute of Biological Sciences (ICB), Federal University of Minas Gerais (UFMG), Brazil. He is also an honorary Scientist at Institute of Integrative Omics and Applied Biotechnology (IIOAB), India. Dr. Kenneth Lundstrom is currently the CEO of PanTherapeutics in Lausanne, Switzerland.He serves on editorial boards of various journals including Biomedicines and Viruses, and acts as Editor-in-chief for Frontiers in Translational Virology. Tab Content 6Author Website:Countries AvailableAll regions |
||||
